top of page

Search Results

Results found for "Domain Therapeutics"

  • From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem

    Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics

  • A Brief History of allosteric modulation with Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics They explored the evolution of the field, allosteric modulation concepts, and potential therapeutic approaches Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for therapeutic Yamina discussed the potential of autoantibodies and allosteric modulation in the context of disease and therapeutic endogenous allosteric ligands and the possibility of using a neutral allosteric ligand as a preferred therapeutic

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis | Dr. GPCR Ecosystem

    Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies

  • Trademark Policy | Dr. GPCR Ecosystem

    restriction is prohibited by applicable law), and you agree not to register or attempt to register any domain For example, you may not use our marks: In domain names As app icons or featured in an app As the most

  • GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem

    From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

  • Dr. Lauren M. Slosky | Dr. GPCR Ecosystem

    protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

  • Yao Lu (Jackie) | Dr. GPCR Ecosystem

    molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

  • irreversible drugs post 1 | Dr. GPCR Ecosystem

    How target depletion and replenishment kinetics define the therapeutic window.

  • Tanishka S. Saraf | Dr. GPCR Ecosystem

    Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

  • Dr. Terry Hébert | Dr. GPCR Ecosystem

    Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

  • Dr. Aurélien Rizk | Dr. GPCR Ecosystem

    the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

  • Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem

    biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

  • irreversible drugs post 3 | Dr. GPCR Ecosystem

    lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic

  • Flash News: Your Hub for GPCR Insights and Scientific Conference Programs

    Michelle describes how reading those early papers on lipid-rich domains and GPCR–G protein compartmentalization translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure. How target depletion and replenishment kinetics define the therapeutic window.

  • Celtarys Research | Dr. GPCR Ecosystem

    One of the best tools to study therapeutic targets are fluorescent ligands, which are very useful in Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

  • irreversible drugs post 2 | Dr. GPCR Ecosystem

    The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure.

  • Dr. Demet Araç | Dr. GPCR Ecosystem

    Demet's research on the gain domain of adhesion GPCRs started during his postdoctoral studies and continued

  • GPCR Courses

    Measuring and understanding bias helps design drugs that maximize therapeutic benefits while minimizing See- The Importance of Pharmacologic Assays Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic Lecture 4: Unconventional GPCR Ligands as Drugs Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic

  • The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem

    She has advanced the use of computational methods to meet the challenges of designing therapeutics with

  • Dr. Fiona Marshall | Dr. GPCR Ecosystem

    As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

  • Dr. Amynah Pradhan | Dr. GPCR Ecosystem

    Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

  • Dr. Aaron Sato | Dr. GPCR Ecosystem

    record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

  • Dr. Nicola J. Smith | Dr. GPCR Ecosystem

    orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

  • Dr. Brian Arey | Dr. GPCR Ecosystem

    His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

  • Dr. Adriano Marchese | Dr. GPCR Ecosystem

    The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic

  • Dr. Andrew Tobin | Dr. GPCR Ecosystem

    vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics

  • Dr. Brian Arey | Dr. GPCR Ecosystem

    His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

bottom of page